Trial · NCT04295642
A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease
NCT04295642, Phase 1, Completed, Cerevel Therapeutics, LLC
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease. Trials, record NCT04295642. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04295642
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease
- NCT number
- NCT04295642
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 24 participants, actual
- Lead sponsor
- Cerevel Therapeutics, LLC
- Conditions
- Parkinson Disease
- Interventions
- CVL-751
- First posted
- 2020-03-04
- Last updated
- 2021-08-31
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Single Dose: Peak Plasma Concentration | Day 1 to 12 | Peak Plasma Concentration (Cmax) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Primary | Single Dose:Area under the plasma concentration-time curve | Day 1 to 12 | Area under the plasma concentration-time curve (AUC) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Primary | Single Dose: Area under the plasma concentration-time curve from time zero to infinity | Day 1 to 12 | Area under the plasma concentration-time curve from time zero to infinity (AUCinf) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Primary | Single Dose: Time to Maximum Concentration | Day 1 to 12 | Time to Maximum Concentration (Tmax) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Primary | Multiple Dose: Peak Plasma Concentration | Day 16 to 29 | Peak Plasma Concentration (Cmax) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Primary | Multiple Dose: Area under the plasma concentration-time curve | Day 16 to 29 | Area under the plasma concentration-time curve (AUCτ) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Primary | Multiple Dose: Time to Maximum Concentration | Day 16 to 29 | Time to Maximum Concentration (Tmax) for CVL-751 and its metabolite (PF-06752844) under fasted and fed conditions |
| Secondary | Secondary Outcome (AE) Number of subjects with reported Treatment Emergent Adverse Events (TEAEs) | up to Day 35 | Number of subjects with reported Treatment Emergent Adverse Events (TEAEs) |
| Secondary | Secondary Outcome (Labs) Number of subjects with clinically significant changes in laboratory measures | up to Day 35 | Number of subjects with clinically significant changes in laboratory measures |
| Secondary | Secondary Outcome (ECGs)Number of subjects with Clinically significant changes in Electrocardiogram | up to Day 35 | Number of subjects with Clinically significant changes in Electrocardiogram measures (PR,RR,QT and QTcF) |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04295642
GET https://conductscience.org/api/trials/v1/NCT04295642/registered